Regencell Bioscience Holdings Limited
Case Overview
| Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 06/23/2026 |
| Status: | Status: Investigating |
| Company Name: | Company Name: Regencell Bioscience Holdings Limited |
| Court: | Court: District of Maryland |
| Case Number: | Case Number: 1:26cv01602 |
| Class Period: | Class Period: 10/28/2024 - 10/31/2025 |
| Ticker: | Ticker: RGC |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Regencell Bioscience Holdings Limited (“Regencell” or the “Company”) (NASDAQ:RGC) securities during the period of October 28, 2024 through October 31, 2025, inclusive (“the Class Period”).
The lawsuit alleges that (i) Regencell was vulnerable and/or subject to market manipulation; (ii) the resulting volatility in the market for the Company's ordinary shares exposed Regencell's investors to significant financial risk; (iii) all the foregoing subjected Regencell to a heightened risk of regulatory and/or governmental scrutiny and enforcement action, as well as significant legal, monetary, and reputational harm; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times.
On October 31, 2025, when Regencell disclosed in a filing with the U.S. Securities and Exchange Commission that "following recent volatility in the market for our Ordinary Shares, the Company received correspondence and a subpoena from the United States Department of Justice (DOJ'), indicating that the DOJ is conducting an investigation into the trading in our Ordinary Shares." Regencell said that "[t]he DOJ has requested the production of documents and communications concerning these and other corporate operational, financial and accounting matters" and that the Company "expect[s] to continue to incur significant legal costs and other expenses in connection with responding to the investigation" and "may be required to pay fines, penalties, damages or settlement costs in excess of our insurance coverage, if any, related to the investigation." On this news, the price of Regencell shares declined by $3.09 per share, or approximately 19%, from $16.65 per share on October 31, 2025 to close at $13.56 on November 3, 2025.